CD44 and prostate cancer: Therefore, the use of Sibilin, Zerumbone, or curcumin/epigallocatechin notably reduced the population of CD44+ tumor cells (breast cancer, pancreatic cancer, and prostate cancer), suggesting a novel approach for the treatment of sarcomas.